チボザニブ

チボザニブ 価格

チボザニブ 化学特性,用途語,生産方法

• 効能

  抗悪性腫瘍薬, 血管新生阻害薬, 受容体チロシンキナーゼ阻害薬

• 特性

  Primary targets: VEGFR/multikinase
  Class: receptor tyrosine kinase
  Treatment: RCC
  Elimination half-life = 111 h
  Protein binding = >99%

• 使用

  Tivozanib also known as AV-951 is an orally bioavailable potent VEGFR-1, 2 and 3, c-Kit and PDGFR inhibitor with IC50 of 0.21, 0.16, 0.24, 1.63 and 1.72 nM, respectively.

• 合成

  The synthesis of Tivozanib is as follows:
  Phenyl chlorocarbonate (601 g) was added dropwise to 3-amino-5-methylisoxazole (377 g), pyridine (1215 g), and N,N-dimethylacetamide (4 L) at 0°C, and the mixture was stirred at 20°C for 2 hr. 4-[(4-Amino-3-chlorophenol)oxy]-6,7-dimethoxyquinoline (847 g) was added to the reaction solution, and the mixture was stirred at 80°C for 5 hr. The reaction solution was cooled to 5°C. Thereafter, methanol (8.5 L) and water (8.5 L) were added thereto, and the mixture was neutralized with an aqueous sodium hydroxide solution. The resultant precipitate was collected by filtration, and the filtered product was slurried in water (8.5 L) for washing. The slurry was filtered, and the filtered product was then dried under the reduced pressure to give Tivozanib (1002 g, yield 86.1%).
  

チボザニブ 生産企業

Global(232)Suppliers

チボザニブ スペクトルデータ(¹HNMR)

475108-18-0, チボザニブ キーワード